文献速递胸部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

局限期小细胞肺癌海马保护预防性颅脑照射的成本效益

Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2017-01-18

本研究通过马尔可夫模型决策分析,比较局限期小细胞肺癌患者接受海马保护预防性颅脑照射(HA-PCI)与传统PCI(C-PCI)的成本效益。以10万美元/QALY为意愿支付阈值,基础分析显示HA-PCI的ICER为47,107美元/QALY,更具成本效益;概率敏感性分析中HA-PCI在68%的迭代中为成本效益策略。

要点

  • HA-PCI较C-PCI的ICER为47,107美元/QALY,低于10万美元/QALY阈值。
  • 脑转移风险未增加至少14%或神经认知障碍率降低至少40%时,HA-PCI更优。
  • 概率敏感性分析中HA-PCI在68%的迭代中为成本效益策略。

核心结论

  • 在局限期小细胞肺癌中,HA-PCI比传统PCI更具成本效益。
  • 若RTOG0933结果被正在进行的NRGCC003试验证实,结果支持在该人群中使用HA-PCI。

研究设计与样本

  • 采用马尔可夫模型模拟接受HA-PCI或传统PCI的局限期小细胞肺癌患者的临床病程。
  • 使用100,000美元/QALY的意愿支付阈值,计算增量成本效果比(ICER),并进行敏感性分析。

主要发现

  • 基础案例中HA-PCI的ICER为47,107美元/QALY。
  • 只要脑转移风险未增加至少14%,或神经认知功能障碍率降低至少40%,HA-PCI即优于传统PCI。
  • 概率敏感性分析中HA-PCI在68%的测试迭代中为成本效益策略。

关键数值与推荐

  • 意愿支付阈值为100,000美元/QALY。
  • HA-PCI的ICER为47,107美元/QALY。
  • 脑转移风险增加至少14%或神经认知障碍率降低至少40%为HA-PCI优于传统PCI的参数阈值。

临床怎么用

  • 在局限期小细胞肺癌患者中,可考虑使用HA-PCI以兼顾成本效益与神经认知保护。
  • 临床决策时应关注脑转移风险与神经认知障碍率的变化是否在上述阈值范围内。

局限性

  • 研究结论基于决策分析模型,尚需NRGCC003试验等前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Prophylactic cranial irradiation (PCI) in limited stage small cell lung cancer (LS-SCLC) prevents brain metastases and improves survival, with the potential for neurocognitive toxicity. RTOG0933 demonstrated that hippocampal avoidance (HA) during whole brain radiotherapy preserves neurocognition. This study's objective was to evaluate the cost-effectiveness of HA-PCI in LS-SCLC through decision analysis. MATERIALS AND METHODS: A Markov model was developed to simulate the clinical course of LS-SCLC who received HA-PCI or conventional PCI (C-PCI). A willingness-to-pay threshold of $100,000/QALY was used. Incremental cost effectiveness ratio was calculated (ICER). Sensitivity analyses were performed to determine the parameter thresholds and to assess the robustness of the model. RESULTS: In the base case scenario, HA-PCI is more cost-effective than C-PCI, with an ICER of $47,107/QALY. HA-PCI was preferred over C-PCI provided that the risk of developing brain metastases was not increased by at least 14%, or if neurocognitive dysfunction rates were reduced by at least 40%. HA-PCI was the cost-effective strategy in 68% of tested iterations in probabilistic sensitivity analysis. CONCLUSION: This study demonstrates that HA-PCI is more cost-effective than C-PCI in LS-SCLC. Our results support the use of HA-PCI in this patient population, should results from RTOG0933 be confirmed by the ongoing NRGCC003 trial.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Qu XM, Mishra MV, Bauman GS, et al. Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiother Oncol. 2017. PMID: 28109544. doi:10.1016/j.radonc.2017.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。